University Hospital Heidelberg, Med. Klinik V
Welcome,         Profile    Billing    Logout  
 3 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Goldschmidt, Hartmut
NCT06216158: Iberdomide Vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma

Recruiting
3
411
Europe
Iberdomide, Isatuximab, Sarclisa, Dexamethasone
University of Heidelberg Medical Center, KKS Netzwerk, Wuerzburg University Hospital, Sanofi, Bristol-Myers Squibb
Multiple Myeloma
12/28
06/29
GMMG-HD7, NCT03617731 / 2017-004768-37: Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

Calendar Jan 2025 - Dec 2025: From GMMG HD7 trial for newly diagnosed multiple myeloma
Jan 2024 - Dec 2024: Submission for newly diagnosed multiple myeloma (transplant eligible)
Hourglass Oct 2021 - Dec 2021 : From first part of trial in newly diagnosed multiple myeloma
Active, not recruiting
3
662
Europe
Lenalidomide, Revlimid, Bortezomib, Velcade, Dexamethasone, Isatuximab
University of Heidelberg Medical Center
Multiple Myeloma
05/25
12/25
NCT05804032 / 2022-000996-38: Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

Recruiting
3
514
Europe
Isatuximab, Sarclisa, Lenalidomide, Bortezomib, Velcade, Dexamethasone
University of Heidelberg Medical Center, Deutsche Studiengruppe Multiples Myelom (DSMM), KKS Netzwerk, Sanofi
Multiple Myeloma
07/25
07/26
Raab, Marc S
DREAMM8, NCT04484623 / 2018-004354-21: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Hourglass Jul 2024 - Dec 2024 : Acceptance of regulatory submission in Japan for 2L+ multiple myeloma (based on DREAMM-8 trial)
Jan 2024 - Dec 2024: Regulatory approval in EU for 2L+ multiple myeloma (based on DREAMM-7 trial)
Jan 2024 - Dec 2024: Regulatory approval in US for 2L+ multiple myeloma (based on DREAMM-7 trial)
Hourglass Jul 2024 - Dec 2024 : Acceptance of regulatory submission in EU for 2L+ multiple myeloma (based on DREAMM-8 trial)
Hourglass Oct 2024 - Dec 2024 : Acceptance of regulatory submission in US for 2L+ multiple myeloma
More
Recruiting
3
357
Europe, Japan, US, RoW
Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib
GlaxoSmithKline
Multiple Myeloma
01/24
05/29
GMMG-BIRMA, NCT02834364: BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)

Completed
2
12
Europe
Encorafenib, LGX818, Binimetinib, MEK162
University of Heidelberg Medical Center, Array BioPharma, German Cancer Research Center, Coordinating Centre for Clinical Trials Heidelberg, University Hospital Heidelberg
Relapsed or Refractory Multiple Myeloma, Patients With BRAFV600 E or BRAFV600K Mutation
03/23
03/23
MajesTEC-5, NCT05695508: GMMG-HD10 / DSMM-XX / 64007957MMY2003,

Recruiting
2
130
Europe
Teclistamab (Tec), JNJ-64007957, Daratumumab, Dexamethasone, Lenalidomide, Bortezomib, Talquetamab
University of Heidelberg Medical Center, Janssen Research & Development, LLC, Deutsche Studiengruppe Multiples Myelom (DSMM)
Multiple Myeloma
02/27
08/28
DREAMM 9, NCT04091126 / 2019-003047-30: Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

Checkmark From DREAMM-9 trial for 1L transplant ineligible multiple myeloma at ASH 2021
Dec 2021 - Dec 2021: From DREAMM-9 trial for 1L transplant ineligible multiple myeloma at ASH 2021
Recruiting
1
144
Europe, Canada, US, RoW
Belantamab mafodotin, Bortezomib, Lenalidomide, Dexamethasone
GlaxoSmithKline
Multiple Myeloma
11/24
06/25

Download Options